Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Raymond

Showing results (21-30 of 173) with videos related to

Pageof 18
Sort By:
Cureus|August 27, 2021
Posterior Reversible Encephalopathy Occurring During Treatment With PalbociclibLahcene Belaidi, Nabil Baba-Hamed, Francesco Savinelli, et al.
Bulletin Du Cancer|December 7, 2007
[Phase I cancer trials methodology]Christophe Le Tourneau, Sandrine Faivre, Eric Raymond, et al.
Drug Safety|August 13, 2009
Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancerNathalie Theou-Anton, Sandrine Faivre, Chantal Dreyer, et al.
Acta Biochimica Polonica|July 26, 2002
Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 statusPrzemyslaw Bozko, Annette K Larsen, Eric Raymond, et al.
Endocrinology and Metabolism Clinics of North America|November 25, 2010
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumorsSandrine Faivre, Marie-Paule Sablin, Chantal Dreyer, et al.
Therapie|June 22, 2007
[Irinotecan and liver dysfunctions]Marie-Paule Sablin, Christophe Le Tourneau, Sandrine Faivre, et al.
Presse Medicale (Paris, France : 1983)|April 10, 2010
[Targeted therapies in hepatocellular carcinoma]Mohamed Bouattour, Hélène Marijon, Chantal Dreyer, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2007
Could we expect to improve survival in small cell lung cancer?Ghassan El Maalouf, Jean-Michel Rodier, Sandrine Faivre, et al.
Targeted Oncology|January 7, 2021
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with SunitinibNicola Fazio, Matthew Kulke, Brad Rosbrook, et al.
Molecular Cancer Therapeutics|December 7, 2002
Cellular and molecular pharmacology of oxaliplatinEric Raymond, Sandrine Faivre, Stephen Chaney, et al.
Pageof 18

Showing results (21-30 of 173) with videos related to

Sort By:
Pageof 18
Cureus|August 27, 2021
Posterior Reversible Encephalopathy Occurring During Treatment With PalbociclibLahcene Belaidi, Nabil Baba-Hamed, Francesco Savinelli, et al.
Bulletin Du Cancer|December 7, 2007
[Phase I cancer trials methodology]Christophe Le Tourneau, Sandrine Faivre, Eric Raymond, et al.
Drug Safety|August 13, 2009
Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancerNathalie Theou-Anton, Sandrine Faivre, Chantal Dreyer, et al.
Acta Biochimica Polonica|July 26, 2002
Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 statusPrzemyslaw Bozko, Annette K Larsen, Eric Raymond, et al.
Endocrinology and Metabolism Clinics of North America|November 25, 2010
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumorsSandrine Faivre, Marie-Paule Sablin, Chantal Dreyer, et al.
Therapie|June 22, 2007
[Irinotecan and liver dysfunctions]Marie-Paule Sablin, Christophe Le Tourneau, Sandrine Faivre, et al.
Presse Medicale (Paris, France : 1983)|April 10, 2010
[Targeted therapies in hepatocellular carcinoma]Mohamed Bouattour, Hélène Marijon, Chantal Dreyer, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2007
Could we expect to improve survival in small cell lung cancer?Ghassan El Maalouf, Jean-Michel Rodier, Sandrine Faivre, et al.
Targeted Oncology|January 7, 2021
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with SunitinibNicola Fazio, Matthew Kulke, Brad Rosbrook, et al.
Molecular Cancer Therapeutics|December 7, 2002
Cellular and molecular pharmacology of oxaliplatinEric Raymond, Sandrine Faivre, Stephen Chaney, et al.
Pageof 18